GILD

Gilead Sciences
D

GILD

Arincen87/100B
166.870
USD
-0.73
(-0.44%)
Pre Open·168.040USD+1.170(+0.70%)
Last updated: · Delayed 15 min

Gilead Sciences P/E ratio

Gilead Sciences's P/E ratio is 44.87: its share price of 166.87 over its earnings per share of -3.10 over the last twelve months.

Today
44.87
Forward P/E, next 12 months
19.53
PEG ratio
3.09
Average, 5 years
98.78
Low, 5 years
10.36
High, 5 years
1,120.10

P/E ratio = price ÷ EPS (last 12 months) = 166.87 ÷ -3.10 = 44.87

Each day's closing price over the earnings per share of the last four quarters reported by that day (basic EPS, adjusted for splits). The P/E moves with the price every day and with the earnings at each report.

The forward P/E divides the price by the analysts' average EPS estimate for the next twelve months: the fiscal year in progress for the months left in it, the next one for the rest. For past days it uses each year's latest estimate, as the estimates of the time were not recorded (we keep a daily copy from November 2026), so the past line reads the price against the earnings expected by the time each year was reported.

P/E ratio by year and by quarter

Fiscal yearPeriod endingP/E ratioForward P/EMarket capNet income
FY2028 · Estimate31 Dec 202815.48———
FY2027 · Estimate31 Dec 202716.52———
Today44.8719.53206.98B4.61B
FY202531 Dec 202517.9411,566.18152.69B8.51B
FY202431 Dec 2024239.9711.38115.19B480.00M
FY202331 Dec 202317.8518.32101.10B5.67B
FY202231 Dec 202223.4612.71107.74B4.59B
FY202131 Dec 202114.7110.2291.20B6.20B
FY202031 Dec 2020595.397.1073.23B123.00M
FY201931 Dec 201915.389.3682.52B5.36B
FY201831 Dec 201814.878.9381.19B5.46B
FY201731 Dec 201720.1610.3393.63B4.64B
FY201631 Dec 20167.118.2295.89B13.49B
FY201531 Dec 20158.188.84148.14B18.11B
FY201431 Dec 201411.907.71143.46B12.06B
FY201331 Dec 201337.5513.40114.80B3.06B
FY201231 Dec 201221.6119.2355.63B2.57B
FY201131 Dec 201111.3711.1231.71B2.79B
FY201031 Dec 201010.748.8031.02B2.89B
FY200931 Dec 200914.9112.1639.15B2.63B
FY200831 Dec 200823.9021.3147.08B1.97B
FY200731 Dec 200726.4624.2142.74B1.62B
FY200631 Dec 2006—21.4029.81B-1.19B
FY200531 Dec 200529.3426.3023.88B813.91M
FY200431 Dec 200433.6526.5215.12B449.37M
FY200331 Dec 2003—48.6011.73B-72.00M
FY200231 Dec 200292.2226.566.65B72.10M
FY200131 Dec 2001119.67164.406.26B52.27M
FY200031 Dec 2000——3.77B-56.78M
FY199931 Dec 1999——2.32B-66.50M
FY199831 Dec 1998——1.68B-44.80M
FY199731 Dec 1997——1.25B-72.90M
FY199631 Dec 1996——694.65M-21.70M
FY199531 Dec 1995——680.77M-27.40M
FY199431 Dec 1994——176.92M-31.30M
FY199231 Dec 1992——308.44M-14.10M
FY199131 Dec 1991——227.81M-4.50M
FY199031 Dec 1990——192.86M-4.00M

Figures in USD. A quarter's revenue, net income and dividends are those of its last four quarters. A forecast year's P/E is today's price over the analysts' EPS estimate for that year.

See also:Market cap,P/S ratio,Dividend yield,ROE (return on equity),Debt to equity,Current ratio,All ratios

Common questions about Gilead Sciences's P/E ratio

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.